drugset / Trial / NCT01687478

A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression

NCT01687478

Phase 3 Terminated 176 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.

Timeline

Start
2012-09
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 15 mg Oral
Background Fluoxetine Small molecule 50 mg Oral

Indications

No indication recorded.